• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The Effects of Different Doses and Patterns of Docetaxel Chemotherapy in Japanese Patients with Castration-Resistant Prostate Cancer.多西他赛不同剂量和化疗方案对日本去势抵抗性前列腺癌患者的影响
Curr Urol. 2017 Aug;10(3):166-168. doi: 10.1159/000447175. Epub 2017 Jul 30.
2
A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.一项关于日本转移性去势抵抗性前列腺癌患者中醋酸阿比特龙序贯多西他赛治疗的多中心回顾性分析。
Jpn J Clin Oncol. 2015 Aug;45(8):774-9. doi: 10.1093/jjco/hyv070. Epub 2015 May 15.
3
The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.多西他赛化疗治疗去势抵抗性前列腺癌的肿瘤学结局和风险分层。
Jpn J Clin Oncol. 2014 Sep;44(9):860-7. doi: 10.1093/jjco/hyu081. Epub 2014 Jun 20.
4
The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer.二甲双胍在多西他赛化疗期间对接受去势抵抗性前列腺癌治疗的糖尿病患者前列腺癌特异性和总生存的影响。
J Urol. 2017 Apr;197(4):1068-1075. doi: 10.1016/j.juro.2016.10.069. Epub 2016 Oct 28.
5
Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.多西他赛为基础的化疗对日本转移性去势抵抗性前列腺癌男性患者的肿瘤学结局。
Urol Oncol. 2013 Aug;31(6):733-8. doi: 10.1016/j.urolonc.2011.06.006. Epub 2011 Jul 22.
6
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.卡巴他赛联合考比司他和泼尼松与单独卡巴他赛和泼尼松治疗多西他赛治疗后转移性去势抵抗性前列腺癌患者（AFFINITY）：一项随机、开放标签、国际、3 期临床试验。
Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9.
7
Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.双重 PI3K/mTOR 抑制剂 NVP-BEZ235 增敏多西他赛治疗去势抵抗性前列腺癌。
J Urol. 2014 Jan;191(1):227-34. doi: 10.1016/j.juro.2013.07.101. Epub 2013 Aug 15.
8
Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.多西他赛与泼尼松治疗去势抵抗性前列腺癌的疗效和安全性：日本多机构回顾性研究
Jpn J Clin Oncol. 2015 Jul;45(7):682-7. doi: 10.1093/jjco/hyv053. Epub 2015 Apr 10.
9
Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry.先前接受过基于多西他赛化疗的转移性去势抵抗性前列腺癌：来自PROXIMA前瞻性注册研究的治疗模式
J Glob Oncol. 2018 Sep;4:1-12. doi: 10.1200/JGO.18.00009.
10
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.醋酸阿比特龙治疗转移性去势抵抗性前列腺癌患者后的后续化疗及治疗模式：COU-AA-302事后分析
Eur Urol. 2017 Apr;71(4):656-664. doi: 10.1016/j.eururo.2016.06.033. Epub 2016 Jul 9.

本文引用的文献

1
Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.多西他赛与泼尼松治疗去势抵抗性前列腺癌的疗效和安全性：日本多机构回顾性研究
Jpn J Clin Oncol. 2015 Jul;45(7):682-7. doi: 10.1093/jjco/hyv053. Epub 2015 Apr 10.
2
Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment.每周低剂量多西他赛联合雌莫司汀治疗日本去势抵抗性前列腺癌：与三周标准剂量治疗相比的疗效和安全性特征。
Int J Clin Oncol. 2014 Feb;19(1):165-72. doi: 10.1007/s10147-013-0536-7. Epub 2013 Mar 1.
3
Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel.转移性去势抵抗性前列腺癌（CRPC）的风险因素可预测多西他赛的长期治疗效果。
PLoS One. 2012;7(10):e48186. doi: 10.1371/journal.pone.0048186. Epub 2012 Oct 30.
4
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.多西他赛联合泼尼松或米托蒽醌联合泼尼松治疗晚期前列腺癌：TAX 327研究的生存数据更新
J Clin Oncol. 2008 Jan 10;26(2):242-5. doi: 10.1200/JCO.2007.12.4008.
5
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.多西他赛联合泼尼松或米托蒽醌联合泼尼松用于晚期前列腺癌治疗
N Engl J Med. 2004 Oct 7;351(15):1502-12. doi: 10.1056/NEJMoa040720.

The Effects of Different Doses and Patterns of Docetaxel Chemotherapy in Japanese Patients with Castration-Resistant Prostate Cancer.

作者信息

Tatenuma Tomoyuki, Kawahara Takashi, Miyoshi Yasuhide, Fujinami Kiyoshi, Ohta Junichi, Kobayashi Kazuki, Kishida Takeshi, Yao Masahiro, Uemura Hiroji

机构信息

Department of Urology, Kanagawa Cancer Center, Yokohama, Japan.

Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.

出版信息

Curr Urol. 2017 Aug;10(3):166-168. doi: 10.1159/000447175. Epub 2017 Jul 30.

DOI:10.1159/000447175
PMID:28878604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5582433/
Abstract
摘要